Skip to main content

Table 4 Odds ratios for breast cancer according to duration for 'any use' of individual SSRIs

From: A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency

No. of SSRI
prescriptions
Any use a
  Cases Controls Unadjusted OR b
(95% CI)
Adjusted OR c
(95% CI)
  n (%) n (%)   
No use d (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
Paroxetine       
1 to 23 94 (6.0) 893 (5.8) 1.05 (0.85, 1.31) 1.05 (0.84, 1.31)
≥24 20 (1.3) 184 (1.2) 1.09 (0.68, 1.73) 1.06 (0.67, 1.69)
Sertraline       
1 to 23 46 (3.1) 518 (3.5) 0.89 (0.65, 1.21) 0.89 (0.65, 1.21)
≥24 10 (0.7) 103 (0.7) 0.97 (0.51, 1.86) 0.98 (0.51, 1.89)
Fluoxetine       
1 to 23 82 (5.3) 893 (5.8) 0.92 (0.72, 1.64) 0.92 (0.71, 1.64)
≥ 24 25 (1.6) 231 (1.5) 1.08 (0.71, 1.64) 1.08 (0.71, 1.64)
Fluvoxamine       
1-23 45 (3.0) 411 (2.8) 1.10 (0.80, 1.50) 1.10 (0.80, 1.51)
≥24 4 (0.3) 52 (0.4) 0.77 (0.28, 2.13) 0.78 (0.28, 2.18)
Citalopram       
1 to 23 27 (1.8) 314 (2.1) 0.86 (0.58, 1.28) 0.85 (0.57, 1.27)
≥24 3 (0.2) 23 (0.2) 1.30 (0.39, 4.35) 1.28 (0.38, 4.27)
  1. OR = odds ratio; CI = confidence interval
  2. a 'Any use' refers to use of individual SSRI of interest alone or in combination with one or more other SSRIs during the exposure time window two or more years prior to index date.
  3. b Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
  4. c Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
  5. d 'No use' (reference category) refers to women with no SSRI prescriptions dispensed two or more years prior to index date.